Elisabetta A.
- Country
- Italy
- Department
- 2605: U.O.C. Ematologia
Research Overview
- INCB 50465-801: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsaclisib (INCB050465)
- Long-term Safety of Asciminib in Patients With Philadelphia Chromosome-Positive CML or ALL Continuing From Parent Studies
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
Data & Insights
Has run more than one trial at 219 of 413 partner sites.
Specializations
Lymphoma Research
This investigator specializes in treating various forms of B-cell lymphomas, with particular emphasis on follicular lymphoma and marginal zone lymphoma. Their research encompasses both aggressive and indolent lymphoma variants.
- B-Cell Non-Hodgkin's Lymphoma
- Advanced Follicular Lymphoma
- Relapsed/Refractory Lymphomas
The investigator focuses on novel therapeutic approaches combining immunotherapy with conventional treatments.
Leukemia Studies
Their expertise extends to the treatment of chronic myeloid leukemia, with specific interest in developing treatment-free remission strategies and investigating novel therapeutic agents.
- Philadelphia Chromosome Positive CML
- Chronic Phase CML
- Treatment-Free Remission Approaches
The research includes comparative studies of various therapeutic agents for newly diagnosed CML patients.
Myelofibrosis Treatment
The investigator conducts research in primary and secondary myelofibrosis, focusing on novel therapeutic combinations and treatment strategies for patients with various risk levels.
- JAK Inhibitor Therapy
- Myeloproliferative Neoplasm-Associated Conditions
- Advanced Stage Disease Management
Their work includes evaluation of innovative treatments for anemia associated with myelofibrosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.